Blue:
After so many shots on goal and nothing to show for BAVI at this point, I am comfortable that if there is value, they will find it. The best indicator of value is what someone is willing to pay. Too many companies have received deals for pre-clinical and even Phase I status. PPHM received nothing. Either BAVI has no value, or PPHM BOD is holding out for an astronomical price, which must be really hard to get when the clinical results do not support such a value.
The key for me is they have skin in the game, a lot more than my $250k. They have millions. They have biotech experience and contacts. I am willing to bet that if there is value they will monetize it. In the meantime, they can grow Avid and dedicate the necessary capital. The director nominee is with a CMO company that grew from $200M to $1.9B market cap. The capital structure of PPHM is too much in tatters thanks to current BOD and mgmt. to hold out any longer to seek the holy grail, while they massively dilute us and line their own pockets, all at our risk only. That formula is so, so out of whack, in my opinion.
I think cleaning house, and righting this ship will get us to positive cash flow much sooner than the current BOD plan. Once the investment community sees the ATM is shut down, I think the share price can grow to some multiple of earnings.
I also think if there if value to BAVI based upon patient subsets, then as Ronin mentioned, let's do a contingent value deal, taking a percentage of something, as opposed to 100% of nothing, since PPHM presently does not have the capital, expertise, business acumen, or IMO corporate and fiscal responsibility or ethics for that matter to get anything commercialized to the increase shareholder value.
Already they have had WAY TOO MANY CHANCES, WAY TOO MANY YEARS, and WAY TOO MANY MILLIONS of dollars or OUR COMPANY.
High time to show them the door, and hope there is pursuit of a more aggressive claw back of the overpayments.
ALL IMO
News 
Market Data 
Discover 
